Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

FARAFARA Cure FA

Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia - open-label trial

OBJECTIVES:

The objective of the study was to test the efficacy, safety and tolerability of triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia (FRDA) patients in a clinical pilot study.

Read More: Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia - open-label trial


About the Author

Jen Farmer

Jen Farmer

Executive Director

SHARE

FacebookTwitterLinkedinShare on Google+
Event C.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News